A series of new heterocycles (4–18) was synthesized by the structural modification of benzimidazole‐2‐thiol (BT, 2‐MBI). The structures of the synthesized compounds were confirmed with the help of high‐resolution mass spectrometry (HRMS) and 1HNMR spectroscopy. High inhibitions of the oxidants such as ABTS and DPPH were observed for compounds 9 [IC50(s) = 167.4 μM (ABTS), 139.5 μM (DPPH)], 10 [IC50(s) = 186.5 μM (ABTS), 155.4 μM (DPPH)], 11 [IC50(s) = 286.1 μM (ABTS), 189.1 μM (DPPH)], 12 [IC50(s) = 310.8 μM (ABTS), 162.2 μM (DPPH)], 14 [IC50(s) = 281.3 μM (ABTS), 205.7 μM (DPPH)], 15 [IC50(s) = 284.1 μM (ABTS), 177.3 μM (DPPH)], and 16 [IC50(s) = 344.7 μM (ABTS), 270.2 μM (DPPH)] as compared with Ascorbic acid [IC50(s) = 340.9 μM (ABTS), 164.3 μM (DPPH)]. The anti‐Alzheimer's activity was performed in vitro against cholinesterase enzymes (AChE, BChE). Compound 11 was able to show significant inhibitions [IC50(s) = 121.2 μM (AChE), 38.3 μM (BChE)] as against that of galantamine [IC50(s) = 139.4 μM (AChE), 40.3 μM (BChE)]. Compound 14 was found as a very good inhibitor of butyrylcholinesterase (IC50 = 35.4 μM) as compared with standard galantamine. Molecular docking was further performed to investigate the mechanism of anticholinesterase activity.